Current stock page

Catalysts

BCRX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

BCRXBioCryst Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$7.61−$0.07 (−0.91%)

Latest quote

  • Momentum
    42
  • Value
    86
  • Quality
    64
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 25, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 59/100

Momentum 42/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 29.75%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 42/100AIQ Edge 6/10 Above Peers
Beat rate
50%
4 of 8 reported periods
Average surprise
-431.6%
Across covered historical reports
Latest result
+52.4%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—$0.09$0.14+52.4%$165.67M$180.29M
Aug 5, 2026—$0.15$0.30+94.6%$183.28M$218.25M
May 6, 2026—$0.06-$2.98-5066.7%$151.12M$156.41M
Feb 26, 2026—$0.07$1.12+1500.0%$151.32M$406.56M
Nov 3, 2025—$0.07$0.06-14.3%$151.32M$159.4M
Aug 4, 2025—$0.03$0.02-33.3%$149.82M$163.35M
May 5, 2025—-$0.07$0.00+100.2%$149.72M$145.53M
Feb 24, 2025—-$0.07-$0.13-85.7%$126.64M$131.53M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
9
Buy
2
Hold
12-month analyst target
$11.00
+44.55% versus current price
Based on 11 analyst observations. Targets are estimates, not predictions.
Low target
$11.00
+44.55% vs latest price
Average target
$11.00
+44.55% vs latest price
High target
$11.00
+44.55% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 25, 2027

Next known earnings or reporting date.

EPS estimate$0.11

Current analyst expectation for the upcoming report.

Revenue estimate$165.24M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score42

Where event reaction would show up first.

AIQ score59/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
11
Average target
$11.00
Target upside
44.55%
Target range
$11.00 - $11.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
gurufocus.com · Oct 21, 2026

BioCryst Pharmaceuticals (BCRX) Gains FDA Nod for New Orladeyo Oral Pellet Formulation

On October 21, 2026, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) announced FDA approval of a new oral pellet version of its flagship drug Orladeyo, expanding it

insidermonkey.com · Oct 15, 2026

BioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble?

BioCryst Pharmaceuticals, Inc.

gurufocus.com · Sep 30, 2026

BCRX Maintained by JP Morgan -- Price Target Raised to $13.00

BioCryst Pharmaceuticals (BCRX) Analyst Rating Update On October 13, 2023, JP Morgan has maintained its Neutral rating on BioCryst Pharma (BCRX) while raisin

finance.yahoo.com · Sep 23, 2026

Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?

Beneath the headline-driven sentiment of biotech investing lies the true engine of value creation: portfolio durability, capital efficiency, and sustainable revenue compounding. Founded on the promise of structure-based drug design, BioCryst Pharmaceuticals (NASDAQ:BCRX) has evolved from a speculative research shop into a commercial-stage rare disease specialist. The company’s core operational drivers now center on maximizing […]

seekingalpha.com · Sep 15, 2026

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

BioCryst Pharmaceuticals, Inc. (BCRX) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 9:15 AM EDTCompany ParticipantsCharles...

Open full news and sentiment

BCRX Catalysts FAQ

What are the next catalysts for BCRX stock?

BCRX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move BCRX stock?

Upcoming events that could move BCRX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could BCRX's next earnings report affect the stock?

BCRX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive BCRX stock higher?

BCRX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt BCRX stock?

BCRX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.